BPC-157 Side Effects: Reports, Risks & Warning Signs

By Peptide Care Index

BPC-157 side effects reported in people include injection-site redness and swelling, headache, gas, shortness of breath, skin and gum darkening, and mood changes. These records don't establish that BPC-157 itself caused each problem or how often it happens. Small studies and an uncontrolled capsule report don't establish long-term safety, and findings don't transfer automatically between products or routes.

That gap matters more than any single symptom. In May 2026, FDA staff reviewed the publicly available evidence they identified and concluded there isn't enough information to describe BPC-157's safety. They also flagged animal results involving blood clotting and the liver, and potential immune reactions with injected or nasal products. Below, every reported problem is matched to where it came from, so you can see what's documented, what's a guess, and what nobody knows yet. (FDA safety assessment, checked October 14, 2026.)

Trouble breathing, swelling of your tongue or throat, chest pain, or fainting after using a product? Call 911 now. These can be emergency signs whatever the cause. Don't wait for an online answer. Emergency allergy signs · Heart-attack symptoms.

BPC-157 safety at a glance

On this page: Is it safe? · Reported side effects · Symptoms now · Human studies · Oral vs injected · Product risk · FDA's findings · Liver and clotting · Cancer · Immune reactions · Mood and lasting symptoms · Who should be careful · Claims checked · Before you pay · How we checked

Is BPC-157 safe? The short answer

BPC-157's safety in people hasn't been established by adequate long-term human research. The five small treatment studies FDA reviewed reported no serious problems, but their size and limited safety monitoring couldn't rule out uncommon or delayed harm. Other records include an uncontrolled four-week capsule summary and a retrospective clinical-notes study, not a reliable safety profile for every form. (FDA review; capsule summary; clinical-notes preprint.)

Here's why "no serious side effects reported" is not the same as "safe." Imagine a side effect that happens to 1 person in 100. Give the product to 12 people, and there's a good chance none of them gets it. The study looks clean. The risk is still there. The largest active-treatment group among the five studies in FDA's review was about 26 people; the separate capsule summary describes 101 people with paired outcome data, but no control group.

FDA's staff put it plainly in their May 2026 review: there is "insufficient clinical safety information to characterize the safety profile" of BPC-157 (FDA BPC-157 briefing, Section II.D.2, checked October 14, 2026). FDA's compounding safety page says the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA safety-risk page, BPC-157 row, page modified April 22, 2026, checked October 14, 2026).

There are also two different sources of risk, and many reports can't tell them apart:

1. The peptide itself. What BPC-157 does in the body over weeks, months, or years.
2. The product in your hand. Whether the vial or capsule actually contains the right substance, at the stated strength, without contamination or harmful impurities.

Our verdict: No serious adverse events were reported in the five small studies FDA reviewed, but that doesn't establish that reactions are rare. Long-term effects, cancer risk, immune reactions, and safety for specific capsules, under-the-skin injections, and nasal sprays remain unresolved. That's a real unknown, not a hidden "yes" or a hidden "no."

BPC-157 side effects: what has actually been reported?

Human records describe symptoms after BPC-157 use, but they don't give a reliable list of common side effects or how often each happens. A symptom that shows up after someone uses a product is called an adverse event; that timing alone doesn't prove the product caused it.

The table below is our evidence matrix. Each row keeps the problem attached to where it was recorded, which product and route were involved, and what the record can and can't tell you. Read the last column before drawing any conclusion.

How to read the evidence types

• Controlled study: people given BPC-157 were compared with people given a dummy treatment (placebo).
• FDA adverse-event report: someone reported a problem to FDA. These records show a problem was reported, not what caused it; voluntary and mandatory reporting rules differ by reporter.
• Clinical-notes study: researchers searched doctors' existing notes after the fact. Symptoms weren't prospectively monitored under a study protocol.
• Animal study: seen in rats or dogs. It may or may not happen in people.
• FDA risk assessment: a potential risk FDA scientists identify from the evidence and product characteristics. Its frequency in people using BPC-157 hasn't been established.

BPC-157 reported-problem matrix

Reported problem: Shortness of breath needing an emergency room visit
Where it was recorded: FDA adverse-event report (FDA briefing, Section II.D.2.b (https://www.fda.gov/media/193343/download))
People, product, and route: 28-year-old man; compounded BPC-157 acetate injected under the skin
Evidence type: FDA adverse-event report
What the record shows: A serious event was reported
What it can't show: Timing, other medicines, and length of use were missing, so cause can't be judged; not a confirmed allergic reaction
Source/check date and historical cutoff: Peptide Care Index, sources checked October 14, 2026. FDA's adverse-event search ran through December 4, 2025; it is not a live count.
Source URL: https://www.fda.gov/media/193343/download

The clinical-notes study's Figure 3 caption groups recorded problems such as mood changes, anxiety, insomnia, headache, rash, nausea, and vomiting under those three categories. Figure 3F labels the middle category “dermatologic/injection-site”; its abstract uses the narrower term “injection-site hypersensitivity.” Its percentages describe what doctors happened to write down, not how often BPC-157 causes harm.

What this matrix tells you. In the small healthy-volunteer controlled study, the most frequently reported complaints (headache and gas) showed no obvious difference from placebo. The serious reports are real events with unknown causes. The animal findings are warnings worth taking seriously, not proof of harm in people. And a problem missing from this selected table is not proof that it has never been studied or cannot happen.

What's not in this matrix. Some websites list kidney stones, raised blood sugar, hot flashes, or fluid retention as BPC-157 side effects, sometimes with exact percentages. The primary records reviewed for this page do not establish those as human BPC-157 side effects or support those percentages. Blood sugar did shift in the animal study, but in both directions: up in some female rats after treatment stopped and down in high-dose male dogs. If a list gives you a percentage, ask where the denominator came from.

Other sources we checked but didn't add to the matrix. FDA also searched its food and supplement complaint system and found three cases, complicated by multi-ingredient supplements, other medicines, and missing details (FDA briefing, Section II.D.2.b). On October 13, 2026, KFF Health News described two FDA reports involving hospitalization, plus personal accounts such as months of fatigue, anxiety, muscle twitching, and loss of pleasure after using a nasal product bought from an online research-chemical seller. We did not inspect those FDA records ourselves, so they stay out of the matrix. They are reports, not proof of cause.

To cite this resource: "Peptide Care Index, BPC-157 Side Effects: Reports, Risks & Warning Signs, reported-problem matrix, sources checked October 14, 2026," reported-problem matrix.

Why three reports don't give you a side-effect rate

A count of reports is not the number of people harmed out of everyone who used BPC-157. To get a rate, you need two numbers: how many people had the problem, and how many people used the product. FDA's report count gives you neither.

Here's the math problem, made simple:

• 3 reports ÷ an unknown number of users = no usable percentage.
• Even if someone knew how many vials were sold, the top number would still be wrong. Not every problem is reported. FDA notes that compounders operating under section 503A generally don't report adverse events to the agency (FDA briefing, footnote 66).
• And each report still has an uncertain cause, a mixed product, or missing details.

So "only three reports" doesn't mean "low risk," and three frightening reports don't mean "high risk." It means the reporting system can't answer the frequency question. The clinical-notes percentages above have the same problem in a different form: they count what doctors happened to write down, not what was systematically checked.

What should you do if symptoms start after BPC-157?

Act on how serious the symptom is, not on a website calling BPC-157 well tolerated. Emergency symptoms need emergency care right away; other new or worsening symptoms deserve a medical assessment that includes the exact product and everything else you took.

Warning signs and when to get care

These are general medical warning signs. They aren't specific to BPC-157, and they aren't proof that BPC-157 caused anything. They tell you how fast to act.

General medical guidance, sources checked October 14, 2026; official sources are linked in each row. This is not a BPC-157-specific diagnostic or severity score.

How urgent	Signs	What to do
Emergency	Trouble breathing or wheezing; swelling of the lips, tongue, face, or throat; hives with dizziness or feeling faint; chest pain or pressure; fainting; sudden severe headache, vision loss, or weakness or numbness on one side	Call 911. These can be signs of severe allergy, heart attack, or stroke; they are not a diagnosis of a BPC-157 reaction.
Same day	Redness that spreads, warmth, increasing pain, pus or drainage at an injection site; fever or chills after injecting; unusual bleeding or bruising; yellow skin or eyes, with or without dark urine	Get medical care today. Spreading redness with warmth and fever can signal a skin infection. New jaundice needs urgent assessment. Severe or uncontrolled bleeding is an emergency, not a reason to wait.
Prompt clinical contact	New darkening of skin or gums; palpitations that keep coming back without the emergency signs above; mood, anxiety, or sleep changes that don't settle; stomach symptoms that persist; new unexplained dark urine	Contact a clinician and bring your product details. A pharmacist can also help review the product and other medicines. Recurring palpitations warrant medical review; worsening symptoms or any emergency sign need faster care.

If you're having thoughts of harming yourself, call or text 988 (the Suicide & Crisis Lifeline) now. Call 911 for immediate physical danger.

Don't take another dose just to test whether it causes the reaction. Contact your treating clinician or pharmacist before any further use. Don't stop medicines a doctor prescribed for something else unless that doctor tells you to.

There's no established BPC-157-specific antidote or self-treatment plan in the evidence reviewed here. A "lower dose" experiment or route switch is not a substitute for care; clinicians can treat problems such as an allergic reaction or infection. Get it assessed.

Bring a useful record to your appointment

A clinician can judge a possible reaction much better with the actual product information than with the name "BPC-157." Write this down on paper or in your own files. Don't type it into a website form.

Your private symptom record (copy or print)

• Product: name on the label, a photo of the label, lot number, full ingredient list (including anything besides BPC-157), and who sold, prescribed, or dispensed it.
• Form and route: capsule, tablet, under-the-tongue strip, nasal spray, cream, or injection, and how you used it. Write down the amount exactly as the label or instructions state it.
• Timeline: dates and times you used it; when the symptom started; what it felt like; whether it's getting better, worse, or staying the same.
• Everything else: other medicines, supplements, peptides, or hormones, and any recent changes. Health conditions to discuss privately with your clinician.
• Contacts: how to reach the seller, prescriber, or pharmacy.

Report the problem to FDA after you've gotten care

You don't have to prove BPC-157 caused a problem to report it. Patients and clinicians can report suspected reactions and product-quality problems through FDA's MedWatch program online or by calling 1-800-FDA-1088. FDA explains what to include on its reporting page.

Why it matters here: FDA notes that 503A compounders generally don't send adverse-event reports, so a report from you or your clinician may be the only way the agency learns about a problem. 503B outsourcing facilities have a statutory adverse-event reporting duty. Reporting is not emergency help. Get care first.

What do the human safety studies actually show?

FDA's 2026 review identified five small human treatment studies describing roughly 80 people exposed to BPC-157, with no serious adverse events reported. None of those five tested a capsule, an under-the-skin shot, or a nasal spray. The wider record also includes a four-week capsule results summary, a completed gummy study without posted results, and a clinical-notes preprint; these are different kinds of evidence, not proof of safety.

These records aren't one big safety trial. They're small studies of specific procedures, two older studies reported in conference abstracts, an uncontrolled capsule summary, registry records, and a new review of health records, each answering a different, narrow question.

Human-safety evidence ledger

Our arithmetic, from FDA Appendix 1: 24 + about 26 + 17 + 12 + 2 ≈ 81 people described as given BPC-157 in the five studies FDA reviewed. "About 26" is FDA's figure; the abstract didn't state the exact size of the BPC-157 group. This is a description of that selected set—not a total of everyone studied or a pooled safety denominator. The 101-person capsule summary and 1,039-person clinical-notes review stay separate because their products, designs, reporting, and exposure accounting differ.

A source inconsistency worth seeing. The clinical-notes preprint reports average use of 2.2 months in its abstract but 74 days in Table 2, both for 130 people with documented duration. We cannot reconcile those values from the public record. Neither is a recommended treatment duration, and missing duration in the other records is not zero.

What the capsule summary adds. The 2024 report says no adverse events were reported over four weeks. That favorable observation belongs in the record, but its statement of “perfect safety” goes further than the design supports. It does not disclose the initial number enrolled, dropout accounting, or detailed safety-collection methods. Its methods describe arginate with SNAC, while the cover shows an acetate-related marker; we have not chemically verified the preparation. The capsule evidence page explains the reported pain findings without treating them as proof of healing.

What FDA found missing. In its review, FDA identified no published treatment studies giving BPC-157 by mouth, under the skin, in the nose, or on the skin. That is a finding about the evidence FDA identified, not a claim that the separate capsule summary and clinical-note observations do not exist. Human drug-handling data were very limited: the rectal-study abstracts reported undetectable levels, with one describing most samples as below the assay's quantification limit. That cannot prove zero absorption. FDA identified no human pharmacokinetic data for oral, under-the-skin, nasal, or skin use, and no published adverse-reaction case reports in its literature search (FDA briefing, Section II.D.2).

Does "no adverse events reported" mean safe?

It means the researchers didn't report a problem in that group, under those conditions, using whatever checking method they chose. It doesn't rule out a less common problem, a problem their follow-up missed, or a problem with a different product or route.

The details matter. Asking a patient by phone months later whether anything went wrong is very different from scheduled check-ups with blood tests. The knee review's follow-up came months after the injections, which tells you something about lasting problems in those 16 people but little about short-term reactions nobody wrote down. The IV pilot did careful blood tests, but in two people over three days. FDA's summary: the studies were short, small, used doses that were likely exploratory, and gave limited safety information (FDA briefing, Section II.D.2.c).

These results are genuinely reassuring about one thing: in supervised settings, nobody in these small groups had a reported serious reaction. They can't support the bigger claim that BPC-157 is safe.

Does the registered oral trial settle the question?

No. A trial registration describes a plan, not results. The oral tablet study listed as NCT02637284 names PharmaCotherapia d.o.o. as sponsor and Hospital Ángeles Tijuana in Mexico as its site, with 42 participants estimated, not confirmed. Its status is "unknown"; its last known status was active, not recruiting; its last update was posted December 22, 2015; and the dates in its written description don't match its structured date fields. No results are posted. That record can't tell you whether swallowed BPC-157 caused side effects, and it shouldn't be described as a completed safety study.

A separate oral gummy record, NCT07752381, lists Parlay Wellness as sponsor, Citruslabs in Las Vegas as the site, 40 actual participants, and an eight-week, single-group study. It records completion on November 1, 2025, but was first posted—and last updated—on August 7, 2026. No results are posted. “Completed” is a sponsor-submitted status, not a safety result, and gummies are not the same formulation as capsules or the older tablets.

For newer trial listings, including a U.S. study after rotator-cuff surgery that was not yet recruiting when checked on October 14, 2026, see our dated BPC-157 trial records and news. A registry entry does not confirm eligibility or that enrollment has opened.

Are oral BPC-157 products safer than injections?

Swallowing a product avoids a needle, and FDA thinks swallowed BPC-157 likely carries less built-in risk of an immune reaction. But the available oral records do not establish overall safety: one uncontrolled capsule summary reports no adverse events, and the tablet and gummy registry records have no posted results. Oral products skip some injection-specific risks; that is not a head-to-head safety finding.

FDA's review explains the difference this way: injected or nasal BPC-157 "may pose a significant risk for immunogenicity" (the ability to trigger an immune response), while the inherent immune risk of swallowed BPC-157 is "likely to be low." FDA adds that it's still concerned about impurities in oral products, which can cause problems of their own (FDA briefing, Section II.D.2.d).

Route-by-route safety evidence

What this means for you. If you're considering a capsule, a shot under the skin, or a nasal spray, the available records don't establish a dependable safety profile for your exact preparation. Avoiding a needle avoids that injection's puncture and injection-site risks; it doesn't fill the rest of the gap. Our guide to what BPC-157 capsule evidence actually shows covers oral formulations, labels, and lab reports in detail.

Is there a proven safe dose or cycle?

No. The evidence doesn't establish a generally safe dose, schedule, or "cycle" for anyone using BPC-157 on their own. Starting low or switching routes doesn't fix the missing human data, the product-identity problem, or the unknown long-term effects. We don't give dosing guidance.

Why the product can matter as much as the peptide

Important BPC-157 risks can come from what's actually in the vial or capsule, not just the peptide itself. FDA found that products sold under the name "BPC-157" can contain different substances, and that certificates in the materials it reviewed often lacked adequate information about specific impurities, bacterial toxins, or clumping that can contribute to reactions.

One name, different substances. "BPC-157" is a common name, not a United States Adopted Name (USAN). FDA notes that BPC-157 free base and BPC-157 acetate are different ingredients, that it has seen multiple salts and related substances sold under the same common name, and that inconsistent naming is a safety risk because a patient "may be dosed with a different bulk drug substance than the physician ordered" (FDA briefing, Section II.A).

What a typical certificate does and doesn't test. FDA found that most BPC-157 certificates of analysis it reviewed reported only purity. Neither withdrawn nomination included test results for specific impurities, peptide clumps, microbial load, or bacterial endotoxins (toxins from bacteria that can cause fever and inflammation if injected).

Clumping matters. Peptides can stick together into clumps (aggregates), especially during storage or after heat or handling. FDA says clumping and impurities can raise the chance of an immune reaction and can't be ruled out for BPC-157 (FDA briefing, Sections II.A and II.D.2.d).

Where users actually get it. In the 2026 clinical-notes review, among 205 users whose source was recorded, 36% got BPC-157 from compounding pharmacies and 35% from gray-market peptide sellers (preprint). One of FDA's three adverse-event reports involved a product labeled "for research purposes only." A research-use label is not a claim of suitability for human treatment, and we don't recommend research-use products for that purpose. A compounded product from a licensed pharmacy should come with more documentation, but compounded drugs aren't FDA-approved, and FDA doesn't verify their safety or quality before they're sold (FDA: Compounding questions and answers).

For a worked example of reading a real BPC-157 lab report, including sterility and endotoxin results, see what one offer and its laboratory report actually prove.

The practical takeaway. You can't fix the missing safety research. You can identify missing product safeguards by checking exactly what you'd be getting, who makes it, who dispenses it, and what was tested, before any money changes hands.

You can't test the molecule yourself, but you can check the offer. Use Peptide Care Index's Find My Peptide Path tool to see the dated BPC-157 access evidence and get the questions to ask about the exact form, the dispensing pharmacy, and what was tested before you pay. It's free and needs no account or email. It doesn't tell you whether BPC-157 is safe for you; that's a conversation for a clinician.

Find My Peptide Path

What FDA's 2026 review found about BPC-157 safety

FDA staff's review, dated May 11, 2026, is a detailed official assessment of BPC-157 safety, and it concluded the evidence weighs against adding BPC-157 free base and acetate to the 503A bulk-substance list. It found too little human safety data, three adverse-event reports with uncertain causes, animal warning signs, possible immune risks, and quality problems with how the ingredient is identified and tested.

FDA prepared the review for its Pharmacy Compounding Advisory Committee's July 23–24, 2026 meeting. It evaluated BPC-157 free base and BPC-157 acetate for nominated use in ulcerative colitis, not every advertised indication. Here's what it found on safety, in plain terms (FDA briefing, checked October 14, 2026):

What happened next. On July 23, 2026, the advisory committee voted 8–6, with one abstention, to recommend adding BPC-157 to the compounding list anyway, according to ABC News (FDA meeting page). That vote is a non-binding recommendation about whether pharmacies may compound it. It didn't produce new safety data or a finding that BPC-157 is safe. Our October 14, 2026 check of FDA materials and the codified 503A list did not identify a final action adding these substances. The vote tally above is attributed to ABC; we did not independently verify a roll-call record. FDA's safety-risk page lists BPC-157 among withdrawn nominations, alongside its safety concerns. For what this means for prescriptions and pharmacies, see BPC-157 FDA approval and compounding status and the FDA compounding list status table.

Liver, blood fats, and blood clotting

In 28-day animal studies, blood-clotting times and liver-related blood tests differed from controls, and FDA called these clinically relevant warning signs. These findings have not been adequately characterized in people. Small human studies included some laboratory monitoring, and the two-person IV pilot reported no clinically significant adverse pattern; it did not settle the clotting or liver questions.

The animal studies were published by Xu and colleagues in 2020. Rats and dogs received daily injections into the muscle for 28 days, followed by 14 days off. The authors designated the highest tested doses as no-observed-adverse-effect levels. FDA disagreed that the findings could be dismissed and said that conclusion "should be interpreted with caution." FDA also noted the paper didn't include its tissue-examination data (FDA briefing, Section II.D.1.d).

Three terms, defined once:

• aPTT (activated partial thromboplastin time): a blood test of how fast blood clots. Shorter can mean a higher clot risk; longer can mean a higher bleeding risk.
• ALT: a liver enzyme. Higher levels can be a sign of liver stress.
• Triglycerides: a type of fat in the blood.

Animal safety signals FDA flagged

How to read this. Animal findings don't prove these effects happen in people, and these studies used injections into muscle, not the routes people commonly use. FDA's point is narrower: the studies were too short and limited to rule these signals out, and FDA did not identify longer repeat-dose toxicology studies to test whether they repeat or whether others appear. Its review also identified no relevant toxicology studies for the nominated oral, under-the-skin, nasal, rectal, or transdermal routes. This is the scope of that review, not a claim that no other animal experiments exist.

Who should pay attention. If you take a blood thinner, have a bleeding or clotting disorder, or have liver disease, these are the findings to raise with your clinician before considering BPC-157. Don't use these numbers to plan your own blood tests or to judge a dose.

Does BPC-157 cause cancer?

The human evidence reviewed here does not establish that BPC-157 causes cancer—or that it doesn't. FDA identified no formal carcinogenicity studies designed to assess whether it causes tumors. The worry is a theory: in lab and animal research, BPC-157 encourages new blood-vessel growth, which tumors also use. Cancer-related experiments and proposed anticancer effects are a different question from long-term cancer safety.

What's actually been done. FDA found no carcinogenicity studies for BPC-157. Those are long animal studies designed to see whether a drug causes tumors, normally expected for medicines people use for six months or more in total. Three standard lab tests found BPC-157 didn't damage genes (FDA briefing, Sections II.D.1.e and II.D.1.g). That's useful, but gene-damage tests are only one part of checking cancer risk.

Where the concern comes from. Researchers think BPC-157's healing effects may come partly from angiogenesis (forming new blood vessels) and from raising growth-factor activity. FDA's review cites lab studies reporting that BPC-157 activates a blood-vessel growth receptor (VEGFR2) and increases growth-hormone receptors in tendon cells. Tumors need new blood vessels to grow, so the theory is that a substance encouraging them could help an existing tumor.

Why it's not settled either way. A 2025 review in Current Reviews in Musculoskeletal Medicine discusses proposed antitumor and anti-wasting effects (McGuire et al. 2025). But the cited records include a melanoma cell-line conference abstract and a cancer-cachexia review, not a human cancer-safety trial. We could not inspect the underlying full experimental reports supporting the claim of reduced tumor growth, so we do not present tumor shrinkage as an established finding here. Reducing cancer-related wasting, inhibiting cells in a dish, and preventing cancer in a person are not the same result. Neither those claims nor a blood-vessel mechanism tells you what happens in a person over years.

Our verdict: Unknown. "No demonstrated human cancer link in these records" is a weak reassurance, because adequate long-term safety evidence is missing. If you have a current or past cancer, or are being checked for one, involve your cancer care team before considering any unapproved product.

Immune and allergic reactions

FDA's most-repeated safety concern is that injected or nasal BPC-157 could provoke the immune system, with outcomes ranging from no noticeable effect to a severe allergic reaction. FDA identified no formal studies of BPC-157 product immunogenicity, so its human frequency is unmeasured, not ruled out.

What immunogenicity means. Your immune system can treat a peptide as foreign and make antibodies against it. FDA says the results can range from antibodies with no symptoms to "life-threatening and catastrophic reactions," and that outcomes are often unpredictable. Antibodies can also make a peptide stop working (FDA briefing, Section II.D.2.d).

What raises the risk, according to FDA:

• Injection under the skin or nasal use (higher than swallowing or rectal use)
• Impurities left from manufacturing
• Clumped peptide molecules
• Storage conditions and formulation

What's been seen. One FDA report described nine days of injection-site redness and swelling (with another peptide injected at the same time). The 2026 clinical-notes review recorded skin/injection-site problems in about 1.4% of documented users; its abstract calls the category injection-site hypersensitivity. Neither tells you how often BPC-157 itself causes an immune reaction.

Can mood changes or other symptoms last after stopping?

People do report anxiety, low mood, insomnia, brain fog, and anhedonia (a reduced ability to feel pleasure) after BPC-157, and a 2026 review of doctors' notes recorded mental-health or nerve-related problems in 1.4% of documented users. No controlled study identified in this review establishes whether BPC-157 causes these symptoms, and there's no established timeline for how long they last.

What the evidence includes.

• The clinical-notes review grouped recorded problems including mood changes, anxiety, insomnia, and headache (preprint). About half of users in that review also used other treatments, most often testosterone (17%), anti-inflammatory painkillers (15%), TB-500 (13%), and steroids (12%), which makes it hard to tell what caused what.
• Personal accounts, such as one KFF Health News described (months of fatigue, anxiety, twitching, and loss of pleasure after a nasal research-chemical product, fading after about a year, with some spells of emotional numbness still reported), describe personal experiences but can't separate BPC-157 from what else was in the product.
• Animal research suggests BPC-157 interacts with the brain's dopamine and serotonin systems; FDA's reference list includes rat studies on both. That's a possible mechanism, not proof of harm or of a "withdrawal syndrome."

Why there's no recovery clock. In animal studies, BPC-157 blood concentrations fell by half in about 5 minutes in dogs and 15 minutes in rats after an IV dose (FDA briefing, Section II.D.1.b). That doesn't tell you when a symptom will end. Symptoms can outlast a substance for many reasons, and some may have nothing to do with it. Nobody can promise you a symptom will pass in a set number of days, and nobody can tell you from forum stories that it's permanent.

What to do. If a mood, sleep, or nerve symptom continues or gets worse after you stop, get it assessed like any other new symptom, and bring your symptom record. Skip "reset" supplements, tapering plans, or switching to another peptide to fix it; none is supported by evidence. If you're having thoughts of harming yourself, call or text 988; call 911 for immediate physical danger.

Long-term risks: what's known

The long-term side effects of BPC-157 are unknown. In the five treatment studies FDA reviewed, repeated dosing lasted no longer than two weeks. The separate capsule summary describes four weeks; an eight-week gummy registry record has no posted results. FDA's reviewed repeat-dose animal toxicology lasted 28 days, and it identified no formal carcinogenicity studies or complete reproductive-safety program.

Meanwhile, real-world use runs longer. Among users in the 2026 clinical-notes review whose duration was recorded, the abstract gives a 2.2-month average and Table 2 gives 74 days; that discrepancy remains unresolved. Some human studies followed people for months after one or two injections, which counts for something, but it's not the same as studying repeated use over months, rare problems, or effects that appear years later.

"Unknown" here doesn't mean "probably fine" or "probably harmful." It means nobody has done the studies that would tell you.

Who should be most careful with BPC-157?

When almost nothing is known, the people with the most to lose from an unknown risk have the strongest reason to avoid BPC-157 or talk with a doctor first. That especially includes pregnancy and breastfeeding, cancer history, bleeding or clotting problems, liver disease, children and teens, and drug-tested athletes.

The old oral tablet study's registration excluded pregnant and breastfeeding women and people being treated for medical conditions (NCT02637284). That's a study's entry rule, not a tested safety warning. With no posted results, it cannot establish safety for the included groups either.

Does BPC-157 interact with other medicines?

We identified no dedicated human drug-interaction study in the sources reviewed here. Those records cannot establish that a particular combination is safe, and mixed-product adverse reports do not isolate a specific interaction. Bring your full list of medicines, supplements, peptides, and hormones to a clinician or pharmacist. Don't stop a prescribed medicine on your own to make room for BPC-157.

BPC-157 safety claims, checked

Marketing often says BPC-157 has "no side effects," is "proven safe," or that a lab certificate settles the question. Here's what the records actually support, using the Peptide Care Access Check: requirement → applicable evidence → check → finding → next question → revision condition. The same labels apply to the narrow evidence claim in each row, not to clinical suitability.

How to read the findings. Supported: the cited evidence shows the statement is true. Contradicted: the cited evidence shows it isn't. Unresolved: the evidence we have doesn't settle it. Conflicting: sources disagree, and we show both. Not applicable: this kind of record can't answer the question, whatever it shows. Each finding applies only to the statement in its row, not to any product or to whether BPC-157 is right for you.

What to check before you pay for BPC-157

You can't change what science doesn't know yet, but you can check for unanswered product questions before adding a purchase to the uncertainty. If you're still considering BPC-157, confirm exactly what you'd be getting and who stands behind it before you pay. If you have symptoms now, follow the care steps first.

Questions to ask any clinic, pharmacy, or seller (copy or print)

1. Is this BPC-157 free base, acetate, arginate, or another form? What's the strength, quantity, finished form, and route, and what other ingredients does it contain?
2. Which pharmacy prepares and dispenses it, and is it licensed to ship to my state?
3. What specific source supports supplying this product to me right now?
4. For an injectable: was this lot tested for sterility and bacterial endotoxin? Can I see the full report, including the test methods and limits?
5. Does the lab report list identified impurities, or only overall purity?
6. Which human evidence supports the claims you make for this form and use, and what's still unknown?
7. If I have a reaction, who do I contact, how fast will they respond, and will you report it to FDA?
8. What will I owe if no prescription is written or the pharmacy can't fill it, which charges are refundable, and what renews automatically?

A clear answer to every question doesn't make BPC-157 safe. It gives you a clearer written account of what is offered and who to call if something goes wrong; it does not authenticate the product or establish a lawful supply route. A vague answer to any of them tells you something too. For the fees to itemize, see BPC-157 cost and published fees; for how prescriptions, pharmacies, and trials actually work, see how to get BPC-157.

If you're weighing a specific offer, the next step is checking that offer, not finding a more reassuring review. Peptide Care Index's Find My Peptide Path puts the dated BPC-157 access evidence, the provider and fee checks, and before-you-pay questions in one place to copy or print. You can use it with a clinic you already know; you don't have to pick a featured provider.

Find My Peptide Path

How we checked the evidence

We read FDA's full 2026 BPC-157 review, FDA's current safety-risk listing, the original human-study records, the four-week capsule summary, a 2026 clinical-notes preprint, complete oral, rotator-cuff, and hamstring trial registry records, and recent reporting. We kept study findings, adverse-event reports, animal findings, and personal accounts separate, and we didn't test any product or examine anyone.

Peptide Care Index is the independent decision and access index for peptide care—helping you understand the route, the cost, the evidence, and the next step before you pay.

For every reported problem, we recorded where it came from, which product and route were involved, how long people were watched, and what the record can't show. We didn't pool different kinds of evidence into one side-effect percentage, because the records don't support one.

What we actually checked

Records inspected (October 14, 2026): FDA's BPC-157 staff review for the July 23–24, 2026 advisory meeting (dated May 11, 2026), including its safety assessment, adverse-event summary, and human-study appendix; FDA's current compounding safety-risk page; the full knee and IV papers and author-hosted full bladder paper; the six-page capsule summary dated August 22, 2024; the full 2026 clinical-notes preprint, including Figure 3 and Table 2; complete NCT02637284, NCT07752381, NCT07803250, and NCT07437547 registry records; KFF Health News and ABC reporting; a 2025 narrative review and the available publisher records for its cancer-related references; FDA's advisory meeting page and the current codified 503A list; WADA records and the official help sources linked above.

Limits: The two rectal studies were available only as conference abstracts, so we relied on FDA's account of them. We read FDA's summary of its adverse-event reports, not the underlying reports, and we didn't inspect the additional case files KFF Health News described. Animal numeric findings are attributed to FDA's analysis of Xu 2020, not an independent reanalysis of raw animal data. The clinical-notes study isn't peer reviewed and contains the duration/category discrepancies noted above. The capsule document is an uncontrolled educational summary, not a verified peer-reviewed full study report; its formulation and safety-collection limits remain. We did not independently verify the committee vote roll call or obtain full primary experimental reports establishing tumor shrinkage.

What we didn't do: We didn't buy or test products, contact study authors, clinics, pharmacies, or FDA, assess any patient, or check any license.

Review and accountability: This work used AI assistance. No clinician, pharmacist, or regulatory specialist reviewed this article. Source dates are shown beside each finding and are separate from this page's publication date.

See how we make money.

Read more about our methodology and editorial standards, or send a correction or updated source.

Other questions about BPC-157 side effects

Is BPC-157 riskier when combined with TB-500?

A reaction to a blend can be harder to attribute to one ingredient. In FDA's skin-and-gum-darkening report, the reaction came back on reuse of a BPC-157 + TB-500 blend, and FDA couldn't separate the two. TB-500's safety record is separate: FDA's safety-risk page says the agency hasn't identified human exposure data for drug products containing the TB-500 fragment. Evidence about full-length thymosin beta-4 doesn't transfer to the TB-500 fragment, or to BPC-157. (FDA's exact fragment entry.)

Will BPC-157 show up on a drug test?

BPC-157 can be targeted by anti-doping testing; that is not a guarantee that every test includes it or will detect a particular exposure. The World Anti-Doping Agency prohibits it at all times. A prescription by itself does not authorize use under sport rules; USADA explains that therapeutic-use exemptions are considered separately. FDA's review identifies analytical research on BPC-157 and its metabolites, but that does not supply a personal detection window. We found no reliable source establishing its inclusion on standard workplace drug panels.

Is BPC-157 from a compounding pharmacy safer than one bought online?

A licensed compounding pharmacy should document what it made and how, which addresses some product risks that research-use sellers don't. But compounded drugs aren't FDA-approved, FDA doesn't check their safety or quality before sale, and FDA notes that 503A compounders generally don't report side effects to the agency. 503B outsourcing facilities have different reporting requirements. Neither source fills the gap in human safety evidence. See BPC-157 FDA approval and compounding status.

How long do BPC-157 side effects last?

The reviewed studies do not establish a typical duration or recovery timeline. In the recorded cases, the injection-site reaction lasted nine days, no further reactions were reported after the person using the skin-darkening blend stopped (resolution time was not stated), and one personal account described symptoms easing after about a year with some emotional-numbness episodes persisting. Those are individual cases, not a typical timeline. Anything that persists or worsens deserves a medical assessment.

Sources

Sources checked October 14, 2026, unless another check date is given. Publication dates belong to the sources; they are not this page's publication date. Access and evidence limits are stated above.

1. U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 free base and BPC-157 acetate), briefing for the July 23–24, 2026 Pharmacy Compounding Advisory Committee. Staff evaluation dated May 11, 2026. Safety assessment in Section II.D; human studies in Appendix 1. FDA staff analysis, not a final agency decision.

2. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. BPC-157 row in the withdrawn-nominations table. Page modified April 22, 2026.

3. U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. Meeting record; advisory recommendations are non-binding.

4. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

5. Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8–13. PubMed 34324435.

6. Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12–17. PubMed 39325560.

7. Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20–24. PubMed 40131143.

8. Venkatakrishnan AJ, et al. Rising use of unapproved BPC-157 ("Wolverine Peptide") and associated patient-reported outcomes curated from clinical notes. Preprints.org, posted September 7, 2026. Not peer reviewed.

9. ClinicalTrials.gov. NCT02637284: PCO-02 safety and pharmacokinetics of BPC-157 tablets. Status unknown; last update posted December 22, 2015; no results posted.

10. McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med. 2025;18(12):611–619.

11. Maxmen A. People say these peptides hurt them. KFF Health News, October 13, 2026. News reporting; describes reports, not causation.

12. ABC News. FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list. July 23, 2026.

13. World Anti-Doping Agency. WADA publishes 2027 Prohibited List. September 21, 2026; effective January 1, 2027.

14. MedlinePlus. Anaphylaxis and Cellulitis. General medical guidance.

15. U.S. Food and Drug Administration. MedWatch: Safety Information and Adverse Event Reporting Program and Reporting serious problems to FDA.

16. OvationLab. Human study of BPC-157 in a delayed-release capsule: summary of results. August 22, 2024. Six-page educational summary; 101 paired outcome records, four weeks, no control group, no adverse events reported; formulation illustration and methods differ. Not established as a peer-reviewed full report.

17. ClinicalTrials.gov. NCT07752381: Parlay Recover peptide gummies. Sponsor-submitted completed eight-week study; 40 actual participants; first/last posted August 7, 2026; no posted results.

18. ClinicalTrials.gov. Complete NCT02637284 record and complete NCT07803250 record. The former has no posted results and contradictory dates; the latter is not yet recruiting, with inconsistent enrollment and control-arm descriptions. Neither is confirmation of enrollment or access. The complete NCT07437547 record was also inspected: it lists recruiting in China, estimated enrollment and no posted results, with inconsistent intervention-to-arm mappings.

19. Lee and Padgett. Original full knee-pain paper; Lee, Walker, and Ayadi. Author-hosted full bladder paper; Lee and Burgess. Original full IV pilot. These supplement the PubMed records above.

20. Centers for Disease Control and Prevention. Signs and symptoms of stroke. National Heart, Lung, and Blood Institute. Heart-attack symptoms. General emergency guidance, not evidence of BPC-157-specific incidence.

21. NHS. Jaundice and heart palpitations. Symptom urgency guidance; U.S. emergency instructions on this page use 911.

22. 988 Suicide & Crisis Lifeline. Official crisis-support destination.

23. World Anti-Doping Agency. Current Prohibited List and 2027 list, S0, page 4. The 2027 list takes effect January 1, 2027. U.S. Anti-Doping Agency. BPC-157 and therapeutic-use-exemption information.

24. Electronic Code of Federal Regulations. 21 CFR 216.23, current displayed codified list inspected October 14, 2026. The list and a panel vote are different records.

25. Kang et al. BPC157 as Potential Agent Rescuing from Cancer Cachexia. Current Pharmaceutical Design, 2018;24:1947–1956. Publisher abstract and bibliographic record inspected; full review not obtained. Radeljak et al. Melanoma cell-line conference abstract, 2004. Bibliographic record only; full experimental text unavailable. Neither is used here as verified evidence of tumor shrinkage or human cancer safety.

26. U.S. Food and Drug Administration. Adverse Event Reporting for Outsourcing Facilities Under Section 503B and CDER contact information. The former explains the statutory reporting duty; the latter confirms MedWatch telephone reporting.